Anti-beta2 glycoprotein1
EstablishedAnti-β2GP1 is one of three antibodies used to classify antiphospholipid syndrome.
This antibody is one of three tested together to diagnose antiphospholipid syndrome, a condition that raises the risk of blood clots and pregnancy complications. Newer diagnostic criteria from 2023 changed exactly how these antibody results are weighed.
Anti-beta2 glycoprotein-1 (anti-β2GP1) is one of three antiphospholipid antibodies used to diagnose antiphospholipid syndrome (APS), an autoimmune clotting disorder associated with recurrent thrombosis and pregnancy loss.
Positive anti-β2GP1 (IgG, IgM, or IgA), alongside anticardiolipin antibodies and lupus anticoagulant, contributes to APS classification when paired with a clinical event (thrombosis or defined pregnancy morbidity).
Measured via ELISA; the 2023 ACR/EULAR APS classification criteria substantially revised how these three antibodies and their titers are weighted, changing diagnostic rates in some populations, including recurrent pregnancy loss patients.
Confirmed APS with anti-β2GP1 positivity typically guides long-term anticoagulation decisions, particularly for patients with prior thrombosis; isolated positivity without a clinical event does not by itself warrant treatment.
Part of the 2023-revised APS classification criteria; requires a clinical event to establish diagnosis.
- 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
- Prevalence of Antiphospholipid Antibody Syndrome Among Patients with Recurrent Pregnancy Loss. (2024). PMC.